Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GTx Estrogen Agonist For Prostate Cancer Looks Effective At Low Doses

This article was originally published in The Pink Sheet Daily

Executive Summary

On the rebound after venous embolisms led to a clinical hold, Capesaris is getting good results at a significantly lower dose than what was used in that fated trial, and GTx is betting the novel estrogen receptor agonist can improve on the efficacy of androgen deprivation therapy while ameliorating its symptoms.

You may also be interested in...



GTx Muscle Wasting Drug Fails, But Data Offer Possible New Path

Enobosarm failed under FDA analysis plan but met European requirements in NSCLC muscle wasting trials, while a potential survival signal may lead to a positive change of plans in the U.S.

GTx Muscle Wasting Drug Fails, But Data Offer Possible New Path

Enobosarm failed under FDA analysis plan but met European requirements in NSCLC muscle wasting trials, while a potential survival signal may lead to a positive change of plans in the U.S.

GTx Muscle Wasting Drug Fails, But Data Offer Possible New Path

Enobosarm failed under FDA analysis plan but met European requirements in NSCLC muscle wasting trials, while a potential survival signal may lead to a positive change of plans in the U.S.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel